Provided by Tiger Trade Technology Pte. Ltd.

iBio

1.21
-0.0200-1.63%
Post-market: 1.260.0542+4.50%19:30 EDT
Volume:184.89K
Turnover:225.84K
Market Cap:77.49M
PE:-3.79
High:1.24
Open:1.24
Low:1.20
Close:1.23
52wk High:3.82
52wk Low:0.7708
Shares:64.31M
Float Shares:52.11M
Volume Ratio:0.60
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3175
EPS(LYR):-0.3175
ROE:-65.70%
ROA:-30.80%
PB:0.90
PE(LYR):-3.79

Loading ...

iBio Initiated at Outperform by Raymond James

Dow Jones
·
Jun 09

Raymond James Initiates iBio at Outperform With $5 Price Target

MT Newswires Live
·
Jun 08

iBio initiated with an Outperform at Raymond James

TIPRANKS
·
Jun 08

Ibio Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $6

THOMSON REUTERS
·
Jun 05

B. Riley Initiates iBio at Buy With $6 Price Target

MT Newswires Live
·
Jun 05

U.S. RESEARCH ROUNDUP-Chipotle Mexican Grill, Honeywell, Tesla

Reuters
·
Jun 05

iBio executives present at Jefferies Global Healthcare Conference

Reuters
·
Jun 03

iBio to Participate in Upcoming Healthcare Investor Conferences

GlobeNewswire
·
Jun 03

iBio doses first patient in Phase 1 trial of obesity drug candidate IBIO-600

Reuters
·
Jun 02

Ibio Becomes a Clinical-Stage Company With First Participant Dosed in Phase 1 Clinical Trial of Ibio-600 in Adults With Obesity

THOMSON REUTERS
·
Jun 02

IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar

TIPRANKS
·
May 30

LifeSci Capital Remains a Buy on Ibio (IBIO)

TIPRANKS
·
May 16

iBio files Form 3 as director Elizabeth Stoner reports no beneficial ownership

Reuters
·
May 15

Oppenheimer Reaffirms Their Buy Rating on Ibio (IBIO)

TIPRANKS
·
May 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR)

TIPRANKS
·
May 13

BRIEF-Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update

Reuters
·
May 13

iBio reports Q3 EPS (7c), consensus (6c)

TIPRANKS
·
May 13

iBio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

iBio Q3 EPS $(0.07) Misses $(0.06) Estimate

Benzinga Earnings
·
May 13

iBio wins Australian clearance to start Phase 1 trial of obesity drug IBIO-600

Reuters
·
May 13